Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study With a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study With a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Posdinemab (Primary)
  • Indications Alzheimer's disease; Cognition disorders; Dementia
  • Focus Therapeutic Use
  • Acronyms Autonomy
  • Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

  • 16 Jan 2026 Planned End Date changed from 30 Dec 2032 to 8 Mar 2026.
  • 24 Jul 2025 According to the Johnson and Johnson Media Release, company announced that the promising new data from this study will be presented at the Alzheimer's Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada.
  • 08 Jan 2025 According to Johnson & Johnson media release, company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to posdinemab, being investigated to treat patients with early Alzheimers disease.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top